PRODUCT INFORMATION



1,2,3-Trieicosapentaenoyl Glycerol

Item No. 10009732

CAS Registry No.: 99660-94-3

Formal Name: (5Z,5'Z,5"Z,8Z,8'Z,8"Z,11Z,11'Z,

> 11"Z,14Z,14'Z,14"Z,17Z,17'Z,17"Z)-5,8,11,14,17-eicosapentaenoic acid,

1,2,3-propanetriyl ester

Synonyms: EPA-TG, Glycerol Trieicosapentaenoate,


TG(20:5/20:5/20:5)

MF: $C_{63}H_{92}O_{6}$ FW: 945.4 **Purity:** ≥98%

Supplied as: A solution in ethanol

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

1,2,3-Trieicosapentaenoyl glycerol (EPA-TG) is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. The solvent dimethyl formamide (DMF) purged with an inert gas can be used. The solubility of EPA-TG in DMF is approximately 10 mg/ml.

EPA-TG is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the ethanolic solution of EPA-TG should be diluted with the aqueous buffer of choice. EPA-TG has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method.

Description

EPA-TG is a glycerol ester of eicosapentaenoic acid (Item Nos. 90110 | 21908), which is an ω -3 fatty acid. An EPA-TG emulsion, administered i.v., lowers leukotriene B₄ production by 40% in polymorphonuclear leukocytes from rabbits and reduces platelet aggregation.^{1,2} It suppresses natural killer cell activity both in vitro and in vivo, in human lymphocytes and murine spleens, respectively, with the in vivo effects lasting up to seven days.3,4

References

- 1. Hamazaki, T. Intravenous infusion of n-3 polyunsaturated fatty acids. Proc. Soc. Exp. Biol. Med. 200(2), 171-173 (1992).
- 2. Urakaze, M., Hamazaki, T., Soda, Y., et al. Infusion of emulsified trieicosapentaenoyl-glycerol into rabbits--the effects on platelet aggregation, polymorphonuclear leukocyte adhesion, and fatty acid composition in plasma and platelet phospholipids. Thromb. Res. 44(5), 673-682 (1986).
- Yamashita, N., Yokoyama, A., Hamazaki, T., et al. Inhibition of natural killer cell activity of human lymphocytes by eicosapentaenoic acid. Biochem. Bioph. Res. Commun. 138(3), 1058-1068 (1986).
- Yamashita, N., Sugiyama, E., Hamazaki, T., et al. Inhibition of natural killer cell activity by eicosapentaenoic acid in vivo and in vitro. Biochem. Biophys. Res. Commun. 150(1), 497-505 (1988).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM